Exegenesis Bio is a biopharmaceutical company focused on gene therapies and oligonucleotide-based drugs with globally leading delivery vector technologies. Founded in 2019 with strong financial backing, the company has built a broad pipeline of innovative genetic medicines and fully integrated manufacturing capabilities. The company is advancing an early to clinical-stage gene therapy pipeline with two initially focused therapeutic areas: CNS and ophthalmology. The company's vision is to develop and increase access to gene therapies for patients around the world.